{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:15:57Z","timestamp":1791353757876,"version":"4.3.1"},"reference-count":93,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2003<\/jats:title>\n                  <jats:p>Bisphosphonates are widely used for the treatment of osteoporosis and are generally well tolerated. However, the United States Food and Drug Administration safety reports have highlighted the issue of renal safety in bisphosphonate-treated patients. All bisphosphonates carry labeled \u201cwarnings\u201d or a contraindication for use in patients with severe renal impairment (creatinine clearance &amp;lt;30 or &amp;lt;35\u2009mL\/min). Data from pivotal trials and their extension studies of bisphosphonates approved for the management of osteoporosis were obtained via PubMed, and were reviewed with support from published articles available on PubMed. Renal safety analyses of pivotal trials of oral alendronate, risedronate, and ibandronate for postmenopausal osteoporosis showed no short-term or long-term effects on renal function. Transient postinfusion increases in serum creatinine have been reported in patients receiving intravenous ibandronate and zoledronic acid; however, studies showed that treatment with these agents did not result in long-term renal function deterioration in clinical trial patients with osteoporosis. All bisphosphonate therapies have \u201cwarnings\u201d for use in patients with severe renal impairment. Clinical trial results have shown that even in elderly, frail, osteoporotic patients with renal impairment, intravenous bisphosphonate therapy administration in accordance with the prescribing information did not result in long-term renal function decline. Physicians should follow guidelines for bisphosphonate therapies administration at all times. \u00a9 2013 American Society for Bone and Mineral Research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/jbmr.2058","type":"journal-article","created":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T17:37:11Z","timestamp":1375378631000},"page":"2049-2059","source":"Crossref","is-referenced-by-count":110,"title":["Renal safety in patients treated with bisphosphonates for osteoporosis: A review"],"prefix":"10.1093","volume":"28","author":[{"given":"Paul D","family":"Miller","sequence":"first","affiliation":[{"name":"Colorado Center for Bone ResearchUniversity of Colorado Health Sciences CenterLakewoodCOUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie A","family":"Jamal","sequence":"additional","affiliation":[{"name":"Women's College HospitalUniversity of TorontoOntarioCanada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Evenepoel","sequence":"additional","affiliation":[{"name":"Nephrology SectionLeuven UniversityLeuvenBelgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[{"name":"Department of Human MetabolismUniversity of SheffieldSheffieldUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Boonen","sequence":"additional","affiliation":[{"name":"Division of Gerontology and GeriatricsLeuven UniversityLeuvenBelgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,8,1]]},"reference":[{"key":"2024020318343563700_jbmr2058-bib-0001","author":"National Osteoporosis Foundation"},{"key":"2024020318343563700_jbmr2058-bib-0002","first-page":"443","article-title":"How to manage postmenopausal osteoporosis","volume":"66","author":"Body","year":"2011","journal-title":"Acta Clin Belg."},{"key":"2024020318343563700_jbmr2058-bib-0003","author":"U.S. Food and Drug Administration (FDA)"},{"key":"2024020318343563700_jbmr2058-bib-0004","author":"U.S. Food and Drug Administration (FDA)"},{"key":"2024020318343563700_jbmr2058-bib-0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron."},{"key":"2024020318343563700_jbmr2058-bib-0006","year":"2011"},{"key":"2024020318343563700_jbmr2058-bib-0007","year":"2011"},{"key":"2024020318343563700_jbmr2058-bib-0008","year":"2011"},{"key":"2024020318343563700_jbmr2058-bib-0009","year":"2011"},{"key":"2024020318343563700_jbmr2058-bib-0010","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s00198-003-1435-y","article-title":"Relationship between age, renal function and bone mineral density in the US population","volume":"14","author":"Klawansky","year":"2003","journal-title":"Osteoporos Int."},{"key":"2024020318343563700_jbmr2058-bib-0011","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1021\/jm020819i","article-title":"Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa)","volume":"45","author":"Widler","year":"2002","journal-title":"J Med Chem."},{"key":"2024020318343563700_jbmr2058-bib-0012","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone."},{"key":"2024020318343563700_jbmr2058-bib-0013","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int."},{"key":"2024020318343563700_jbmr2058-bib-0014","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.tiv.2008.01.006","article-title":"Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety","volume":"22","author":"Luhe","year":"2008","journal-title":"Toxicol In Vitro."},{"key":"2024020318343563700_jbmr2058-bib-0015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/ki.1975.70","article-title":"Renal secretion of diphosphonates in rats","volume":"8","author":"Troehler","year":"1975","journal-title":"Kidney Int."},{"key":"2024020318343563700_jbmr2058-bib-0016","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/ncpneph0076","article-title":"Drug-associated renal dysfunction and injury","volume":"2","author":"Choudhury","year":"2006","journal-title":"Nat Clin Pract Nephrol."},{"key":"2024020318343563700_jbmr2058-bib-0017","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0140-6736(83)91465-4","article-title":"Renal failure associated with intravenous diphosphonates","volume":"1","author":"Bounameaux","year":"1983","journal-title":"Lancet."},{"key":"2024020318343563700_jbmr2058-bib-0018","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","article-title":"Bisphosphonates: mechanisms of action","volume":"19","author":"Fleisch","year":"1998","journal-title":"Endocr Rev."},{"key":"2024020318343563700_jbmr2058-bib-0019","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0773.1997.tb01964.x","article-title":"Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models","volume":"80","author":"Green","year":"1997","journal-title":"Pharmacol Toxicol."},{"key":"2024020318343563700_jbmr2058-bib-0020","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int."},{"key":"2024020318343563700_jbmr2058-bib-0021","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1093\/ndt\/gfm209","article-title":"Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient","volume":"22","author":"Bodmer","year":"2007","journal-title":"Nephrol Dial Transplant."},{"key":"2024020318343563700_jbmr2058-bib-0022","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1159\/000132707","article-title":"Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases","volume":"80","author":"Joensuu","year":"2008","journal-title":"Urol Int."},{"key":"2024020318343563700_jbmr2058-bib-0023","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1445-5994.2005.00949.x","article-title":"Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma","volume":"35","author":"Henley","year":"2005","journal-title":"Intern Med J."},{"key":"2024020318343563700_jbmr2058-bib-0024","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.10-90001-3","article-title":"Preclinical perspectives on bisphosphonate renal safety","volume":"10","author":"Body","year":"2005","journal-title":"Oncologist."},{"key":"2024020318343563700_jbmr2058-bib-0025"},{"key":"2024020318343563700_jbmr2058-bib-0026","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00002018-200124010-00003","article-title":"Anticancer drug-induced kidney disorders","volume":"24","author":"Kintzel","year":"2001","journal-title":"Drug Saf."},{"key":"2024020318343563700_jbmr2058-bib-0027","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/sj.bjc.6605979","article-title":"Cancer and renal insufficiency results of the BIRMA study","volume":"103","author":"Janus","year":"2010","journal-title":"Br J Cancer."},{"key":"2024020318343563700_jbmr2058-bib-0028","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/asheducation-2010.1.431","article-title":"Renal insufficiency and failure","volume":"1","author":"Dimopoulos","year":"2010","journal-title":"Hematology."},{"key":"2024020318343563700_jbmr2058-bib-0029","first-page":"635","article-title":"Hypercalcemia in malignancy","volume":"153","author":"Strewler","year":"1990","journal-title":"West J Med."},{"key":"2024020318343563700_jbmr2058-bib-0030","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer."},{"key":"2024020318343563700_jbmr2058-bib-0031","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst."},{"key":"2024020318343563700_jbmr2058-bib-0032","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1359\/jbmr.070112","article-title":"Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial","volume":"22","author":"Jamal","year":"2007","journal-title":"J Bone Miner Res."},{"key":"2024020318343563700_jbmr2058-bib-0033","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","article-title":"Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res."},{"key":"2024020318343563700_jbmr2058-bib-0034","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res."},{"key":"2024020318343563700_jbmr2058-bib-0035","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis 1-year results from the MOBILE study","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res."},{"key":"2024020318343563700_jbmr2058-bib-0036","first-page":"488","article-title":"Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study","volume":"35","author":"Eisman","year":"2008","journal-title":"J Rheumatol."},{"key":"2024020318343563700_jbmr2058-bib-0037","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"key":"2024020318343563700_jbmr2058-bib-0038","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med."},{"key":"2024020318343563700_jbmr2058-bib-0039","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet."},{"key":"2024020318343563700_jbmr2058-bib-0040","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.bone.2011.09.035","article-title":"Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease\u2014the DIVINE study","volume":"49","author":"Miller","year":"2011","journal-title":"Bone."},{"key":"2024020318343563700_jbmr2058-bib-0041","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet."},{"key":"2024020318343563700_jbmr2058-bib-0042","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture Intervention Trial. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318343563700_jbmr2058-bib-0043","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA."},{"key":"2024020318343563700_jbmr2058-bib-0044","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA."},{"key":"2024020318343563700_jbmr2058-bib-0045","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/08860220701260776","article-title":"The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women","volume":"29","author":"Yanik","year":"2007","journal-title":"Ren Fail."},{"key":"2024020318343563700_jbmr2058-bib-0046","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study","volume":"54","author":"Delmas","year":"2006","journal-title":"Arthritis Rheum."},{"key":"2024020318343563700_jbmr2058-bib-0047","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/ki.2008.193","article-title":"Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women","volume":"74","author":"Boonen","year":"2008","journal-title":"Kidney Int."},{"key":"2024020318343563700_jbmr2058-bib-0048","first-page":"S197","article-title":"Renal effects of treatment with zoledronic acid: results from the HORIZON-PFT extension study","volume":"23","author":"Miller","year":"2012","journal-title":"Osteoporos Int."},{"key":"2024020318343563700_jbmr2058-bib-0049","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Regnister","year":"2000","journal-title":"Osteoporos Int."},{"key":"2024020318343563700_jbmr2058-bib-0050","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","article-title":"Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study","volume":"65","author":"Reginster","year":"2006","journal-title":"Ann Rheum Dis."},{"key":"2024020318343563700_jbmr2058-bib-0051","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024020318343563700_jbmr2058-bib-0052","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"N Engl J Med."},{"key":"2024020318343563700_jbmr2058-bib-0053"},{"key":"2024020318343563700_jbmr2058-bib-0054","first-page":"419","article-title":"Ageing and the glomerular filtration rate: truths and consequences","volume":"120","author":"Glassock","year":"2009","journal-title":"Trans Am Clin Climatol Assoc."},{"key":"2024020318343563700_jbmr2058-bib-0055","doi-asserted-by":"crossref","first-page":"c19","DOI":"10.1159\/000314545","article-title":"Chronic kidney disease in older people: physiology, pathology or both","volume":"116","author":"Abdelhafiz","year":"2010","journal-title":"Nephron Clin Pract."},{"key":"2024020318343563700_jbmr2058-bib-0056","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7326\/0003-4819-154-1-201101040-00003","article-title":"Alberta Kidney Disease Network. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study","volume":"154","author":"Tonelli","year":"2011","journal-title":"Ann Intern Med."},{"key":"2024020318343563700_jbmr2058-bib-0057","first-page":"S1","article-title":"KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"Am J Kidney Dis."},{"key":"2024020318343563700_jbmr2058-bib-0058","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1001\/archinte.167.2.133","article-title":"Renal function and risk of hip and vertebral fractures in older women","volume":"167","author":"Ensrud","year":"2007","journal-title":"Arch Intern Med."},{"key":"2024020318343563700_jbmr2058-bib-0059","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1681\/ASN.2006050546","article-title":"Association of kidney function with incident hip fracture in older adults","volume":"18","author":"Fried","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"2024020318343563700_jbmr2058-bib-0060","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00198-011-1781-0","article-title":"Fracture risk assessment in patients with chronic kidney disease","volume":"23","author":"Jamal","year":"2012","journal-title":"Osteoporos Int."},{"key":"2024020318343563700_jbmr2058-bib-0061","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.semnephrol.2003.08.010","article-title":"Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy","volume":"24","author":"Hruska","year":"2004","journal-title":"Semin Nephrol."},{"key":"2024020318343563700_jbmr2058-bib-0062","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bone.2010.12.024","article-title":"The kidney and bisphosphonates","volume":"49","author":"Miller","year":"2011","journal-title":"Bone."},{"key":"2024020318343563700_jbmr2058-bib-0063","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1681\/ASN.2010121275","article-title":"Determinates of prevalent fractures in chronic kidney disease","volume":"22","author":"Nickolas","year":"2011","journal-title":"J Am Soc Nephro."},{"key":"2024020318343563700_jbmr2058-bib-0064","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2215\/CJN.05320512","article-title":"BMD and fracture risk in CKD: where should we go from here","volume":"7","author":"Nickolas","year":"2012","journal-title":"Clin J Am Soc Nephrol."},{"key":"2024020318343563700_jbmr2058-bib-0065","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int."},{"key":"2024020318343563700_jbmr2058-bib-0066","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA."},{"key":"2024020318343563700_jbmr2058-bib-0067","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/jbmr.170","article-title":"FGF-23: more than a regulator of renal phosphate handling","volume":"25","author":"J\u00fcppner","year":"2010","journal-title":"J Bone Miner Res."},{"key":"2024020318343563700_jbmr2058-bib-0068","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1007\/s00198-010-1444-6","article-title":"Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five year study","volume":"22","author":"Sambrook","year":"2011","journal-title":"Osteoporos Int."},{"key":"2024020318343563700_jbmr2058-bib-0069","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5301\/jn.5000212","article-title":"Osteoporosis and adynamic bone in chronic kidney disease","volume":"26","author":"Cannata-And\u00eda","year":"2013","journal-title":"J Nephrol."},{"key":"2024020318343563700_jbmr2058-bib-0070","volume-title":"UpToDate","author":"Miller","year":"2013"},{"key":"2024020318343563700_jbmr2058-bib-0071","first-page":"117","article-title":"Adynamic bone disease: an update and overview","volume":"18","author":"Coen","year":"2005","journal-title":"J Nephrol."},{"key":"2024020318343563700_jbmr2058-bib-0072","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1525-139X.2007.00300.x","article-title":"Renal osteodystrophy, phosphate homeostasis, and vascular calcification","volume":"20","author":"Hruska","year":"2007","journal-title":"Semin Dial."},{"key":"2024020318343563700_jbmr2058-bib-0073","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrendo.2012.36","article-title":"Arterial calcification and bone physiology: role of the bone-vascular axis","volume":"8","author":"Thompson","year":"2012","journal-title":"Nat Rev Endocrinol."},{"key":"2024020318343563700_jbmr2058-bib-0074","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1097\/01.ASN.0000129337.50739.48","article-title":"Arterial calcifications and bone histomorphometry in end-stage renal disease","volume":"15","author":"London","year":"2004","journal-title":"J Am Soc Nephrol."},{"key":"2024020318343563700_jbmr2058-bib-0075","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MNH.0b013e32832c4df0","article-title":"Adynamic bone disease: clinical and therapeutic implications","volume":"18","author":"Fraz\u00e3o","year":"2009","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"2024020318343563700_jbmr2058-bib-0076","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11926-012-0243-9","article-title":"Bone and kidney disease: diagnostic and therapeutic implications","volume":"14","author":"Jamal","year":"2012","journal-title":"Curr Rheumatol Rep."},{"key":"2024020318343563700_jbmr2058-bib-0077","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2215\/CJN.09580911","article-title":"PTH: a particularly tricky hormone: why measure it at all in kidney patients","volume":"8","author":"Garrett","year":"2013","journal-title":"Clin J Am Soc Nephrol."},{"key":"2024020318343563700_jbmr2058-bib-0078","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11606-008-0850-3","article-title":"High prevalence of stage 3 chronic kidney disease in older adults despite normal serum creatinine","volume":"24","author":"Duru","year":"2009","journal-title":"J Gen Intern Med."},{"key":"2024020318343563700_jbmr2058-bib-0079","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.V74556","article-title":"Effects of diet and antihypertensive therapy on creatinine clearance and serum creatinine concentration in the Modification of Diet in Renal Disease Study","volume":"7","author":"Levey","year":"1996","journal-title":"J Am Soc Nephrol."},{"key":"2024020318343563700_jbmr2058-bib-0080","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med."},{"key":"2024020318343563700_jbmr2058-bib-0081","author":"National Kidney Disease Education Program"},{"key":"2024020318343563700_jbmr2058-bib-0082","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/rheumatology\/keg023","article-title":"Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment","volume":"42","author":"Kingdon","year":"2002","journal-title":"Rheumatology."},{"key":"2024020318343563700_jbmr2058-bib-0083","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","article-title":"Assessing kidney function--measured and estimated glomerular filtration rate","volume":"354","author":"Stevens","year":"2006","journal-title":"N Engl J Med."},{"key":"2024020318343563700_jbmr2058-bib-0084","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med."},{"key":"2024020318343563700_jbmr2058-bib-0085","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1053\/j.ajkd.2010.11.007","article-title":"Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP)","volume":"57","author":"Stevens","year":"2011","journal-title":"Am J Kidney Dis."},{"key":"2024020318343563700_jbmr2058-bib-0086","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-2369-13-42","article-title":"Comparing the association of GFR estimated by the CKD-EPI and MDRD study equations and mortality: the third national health and nutrition examination survey (NHANES III) examination survey (NHANES III)","volume":"13","author":"Shafi","year":"2012","journal-title":"BMC Nephrol."},{"key":"2024020318343563700_jbmr2058-bib-0087","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3949\/ccjm.76a.08108","article-title":"Fragility fractures in chronic kidney disease: an opinion-based approach","volume":"76","author":"Miller","year":"2009","journal-title":"Cleve Clin J Med."},{"key":"2024020318343563700_jbmr2058-bib-0088","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/ki.2012.227","article-title":"Oral bisphosphonate use in the elderly is not associated with acute kidney injury","volume":"82","author":"Shih","year":"2012","journal-title":"Kidney Int."},{"key":"2024020318343563700_jbmr2058-bib-0089","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jama.2011.451","article-title":"A predictive model for progression of chronic kidney disease to kidney failure","volume":"305","author":"Tangri","year":"2011","journal-title":"JAMA."},{"key":"2024020318343563700_jbmr2058-bib-0090","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD\u2013MBD)","volume":"76","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD\u2013MBD Work Group","year":"2009","journal-title":"Kidney Int."},{"key":"2024020318343563700_jbmr2058-bib-0091","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int."},{"key":"2024020318343563700_jbmr2058-bib-0092","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1210\/jc.2012-1027","article-title":"Benefits and risks of bisphosphonate therapy for osteoporosis","volume":"97","author":"Khosla","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318343563700_jbmr2058-bib-0093","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday","volume":"126","author":"McClung","year":"2013","journal-title":"Am J Med."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.2058","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/10\/2049\/56562510\/jbmr2058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/10\/2049\/56562510\/jbmr2058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:50:09Z","timestamp":1710341409000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/28\/10\/2049-2059\/7598532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,1]]},"references-count":93,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,8,1]]},"published-print":{"date-parts":[[2013,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.2058","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,10,1]]},"published":{"date-parts":[[2013,8,1]]}}}